Alltracel Signs Nanotechnology Development Partnership for m-doc(TM) Based Woundcare Applications

    DUBLIN, Ireland and PRAGUE, Czech Republic, May 11 /PRNewswire-FirstCall/
 -- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:
 AP.L), the healthcare technology company focussed on the consumer woundcare,
 oral care and coronary health markets, today announces the signing of a
 technology and product development agreement with nanofibre technology
 specialists ELMARCO s.r.o. ("Elmarco") of the Czech Republic for the
 development of a next generation delivery platform for Alltracel's m-doc(TM)
 technology.
     Elmarco (www.elmarco.cz/en_profil.php) is a specialist R&D and
 manufacturing company specialising in advanced manufacturing for the
 semi-conductor components industry as well as equipment for industrial
 production of nanofibrous non-woven materials.
     Together with the Textiles Faculty of the Technical University of
 Liberic, Elmarco have developed a novel, proprietary & patented process for
 spinning polymers into nano-scale fibres for a range of industrial, chemical,
 micro-electronic and bio-medical applications.
     Over the past few months m-doc(TM) based nanofibre woundcare prototypes
 have been developed and are now at an advanced stage of technical evaluation.
     Alltracel's CEO Tony Richardson commented, "Alltracel has always been
 committed to innovation in our markets and we are particularly excited by the
 prospects for m-doc(TM) based nanofibrous advanced woundcare delivery systems.
     Although at an early stage of development nanofibre technology is showing
 market transforming potential in a number of our markets and we are delighted
 to have formalised our partnership with Elmarco and the nanofibre technology
 team at the Technical University of Liberic.
     We are now focussed on jointly reviewing a range of patent protected
 potential applications for m-doc(TM) based nanofibre solutions, initially for
 the advanced woundcare and surgical markets and bringing these innovations to
 market via our network of existing and new commercial partners."
     Notes to Editors
     Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc
 is a Healthcare Technology Company focussed on the Consumer Woundcare,
 Oral-Care and Coronary Health markets.
     With corporate headquarters in Dublin, Ireland; Alltracel has a
 commercial office in London, England; R&D subsidiary in the Czech Republic
 and manufacturing facilities in Shenzhen, China.
     Alltracel was founded in 1996 and listed on London's Alternative
 Investment Market in July 2001.
     m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the
 end product of Alltracel's patented process and is currently targeting two
 major markets.
     - In the Consumer HealthCare market this process applied to cotton in the
 form of raw cellulose is proven as an effective and efficient haemostatic
 (blood-stopping) agent. Here m-doc(TM) is currently being marketed as the
 leading stops bleeding ingredient brand within recognized wound care, oral
 care and relevant first aid brands worldwide.
     - In the Coronary Health market, EU based pre-clinical and patient
 studies have demonstrated the m-doc(TM) technology platform success in
 lowering cholesterol and have indicated longer term coronary health benefits.
 In addition pre-clinical work showed significant indications that the
 m-doc(TM) coronary health benefits are additive in nature, to both statins
 and sterols. Further efficacy, dosage and timing/phasing studies to determine
 optimum delivery systems, formats and combinations in both the nutraceutical
 and pharmaceutical markets are underway. Development discussions with
 potential partners in the nutraceutical and pharmaceutical sectors in both
 the EU and North America have commenced.
     blotters(TM) is Alltracel's branded blood stopping thin film technology
 for the consumer first aid and grooming markets. The blotters(TM) are small,
 thin, film strips (similar to breath freshener strips) impregnated with
 m-doc(TM) - Alltracel's unique blood stopping ingredient and are packed in a
 convenient pocket-sized plastic dispenser. When placed on minor cuts e.g.
 shaving nicks m-doc(TM) is released on contact with the blood, forming a soft
 gel-like layer over the wound to stop the bleeding fast.
     SEAL-ON(TM) (www.seal-on.com ) is the world's first first-aid treatment
 brand featuring stops bleeding m-doc(TM) as standard. The SEAL-ON(TM) range
 features seven different product delivery systems - sprays, nasal plugs,
 patches, powder, plasters, dressings and blotters(TM) -- each designed for
 specific usage occasions and all containing the stops-bleeding m-doc(TM)
 ingredient brand.
     m-doc(TM), blotters(TM), SEAL-ON(TM) are all trademarks of Alltracel
 Pharmaceuticals Plc.
 
     For further information contact:
 
     Dublin: Denise Cronin
     Alltracel: +353-1-235-2162
     press@alltracel.com
 
     London: Deborah Scott/Davina Langdale
     Financial Dynamics: +44-207-831-3113
 
     New York: Sean Leous
     Financial Dynamics: +1-212-850-5626
 
 
 

SOURCE Alltracel Pharmaceuticals Plc

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.